The accelerated approval pathway provides incredible benefit to patients with serious unmet medical need, and there’s data to back it up.| Bio.News
The Centers for Medicare & Medicaid Services (CMS) issued a directive telling private insurers providing Medicare Advantage (MA) plans to cover Biogen’s amyotrophic lateral sclerosis […]| Bio.News
Personal site for posts about my interests: the biotech industry, medicine, molecular biology, neuroscience, biorisk, science, consciousness, AI, innovation, decision making, philosophy, games, sci-fi, probability, and forecasting (among other things). I write to learn, mostly about biotech.| Alex’s blog
FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The approval was based o| U.S. Food and Drug Administration